Artificial Liver Support with CytoSorb and MARS in Liver Failure: A Retrospective Propensity Matched Analysis.
CytoSorb
acute liver failure
acute-on-chronic liver failure
artificial liver support
liver support therapy
molecular adsorbent recirculating system
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
14 Mar 2023
14 Mar 2023
Historique:
received:
13
02
2023
revised:
06
03
2023
accepted:
13
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Liver failure represents a life-threatening organ dysfunction with liver transplantation as the only proven curable therapy to date. Liver assist devices have been extensively researched to either bridge such patients to transplantation or promote spontaneous recovery. The aim of our study was to compare two such devices, the Molecular Adsorbent Recirculating System (MARS) and CytoSorb, in patients with liver failure. We retrospectively included 15 patients who underwent MARS during their intensive care unit stay and matched them to 15 patients who underwent hemoadsorption using CytoSorb. Clinical and paraclinical data obtained after each individual session, after the course of treatment, as well as at the end of the intensive care unit stay were compared between the two groups. Single sessions of CytoSorb and MARS were both associated with a significant decrease in bilirubin ( In conclusion, our results show a potential benefit of CytoSorb in rebalancing liver functional tests in patients with liver failure compared to MARS but the exact effects on patient outcome, including hospital length of stay and survival, should be further investigated in randomized control trials.
Sections du résumé
BACKGROUND
BACKGROUND
Liver failure represents a life-threatening organ dysfunction with liver transplantation as the only proven curable therapy to date. Liver assist devices have been extensively researched to either bridge such patients to transplantation or promote spontaneous recovery. The aim of our study was to compare two such devices, the Molecular Adsorbent Recirculating System (MARS) and CytoSorb, in patients with liver failure.
METHODS
METHODS
We retrospectively included 15 patients who underwent MARS during their intensive care unit stay and matched them to 15 patients who underwent hemoadsorption using CytoSorb. Clinical and paraclinical data obtained after each individual session, after the course of treatment, as well as at the end of the intensive care unit stay were compared between the two groups.
RESULTS
RESULTS
Single sessions of CytoSorb and MARS were both associated with a significant decrease in bilirubin (
CONCLUSION
CONCLUSIONS
In conclusion, our results show a potential benefit of CytoSorb in rebalancing liver functional tests in patients with liver failure compared to MARS but the exact effects on patient outcome, including hospital length of stay and survival, should be further investigated in randomized control trials.
Identifiants
pubmed: 36983259
pii: jcm12062258
doi: 10.3390/jcm12062258
pmc: PMC10058971
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Hepatobiliary Pancreat Dis Int. 2019 Oct;18(5):403-411
pubmed: 31303562
Blood Purif. 2020;49(1-2):107-113
pubmed: 31434083
Transplantation. 2021 Mar 1;105(3):561-568
pubmed: 32568955
Aliment Pharmacol Ther. 2018 Jun;47(11):1502-1510
pubmed: 29611203
Crit Care Res Pract. 2019 Jan 28;2019:3737083
pubmed: 30834144
Liver Int. 2018 Feb;38(2):248-257
pubmed: 28646630
Hepatology. 2016 Oct;64(4):1249-64
pubmed: 27483394
Hepatology. 2019 Jan;69(1):258-269
pubmed: 30070381
AACN Adv Crit Care. 2016 Oct;27(4):420-429
pubmed: 27959298
J Intensive Care Soc. 2019 May;20(2):174-181
pubmed: 31037112
Blood Purif. 2017;44(2):98-99
pubmed: 28355595
J Hepatol. 2013 Jul;59(1):74-80
pubmed: 23439263
Transplant Proc. 2005 Jul-Aug;37(6):2557-9
pubmed: 16182742
Blood Purif. 2021;50(1):119-128
pubmed: 32615564
J Clin Med. 2021 Apr 06;10(7):
pubmed: 33917431
N Engl J Med. 2013 Dec 26;369(26):2525-34
pubmed: 24369077
J Clin Med. 2021 Nov 05;10(21):
pubmed: 34768702
J Hepatol. 2018 Aug;69(2):406-460
pubmed: 29653741
Ann Intern Med. 2016 Jun 7;164(11):724-32
pubmed: 27043883
Int J Artif Organs. 2016 May 16;39(3):136-40
pubmed: 27079418
World J Crit Care Med. 2021 Jan 9;10(1):22-34
pubmed: 33505870
Crit Care. 2006;10(6):R169
pubmed: 17156425
Liver Int. 2009 Apr;29(4):536-43
pubmed: 18795898
Liver Transpl. 2003 Mar;9(3):290-7
pubmed: 12619027
J Gastroenterol Hepatol. 2013 Aug;28(8):1361-7
pubmed: 23488990
Gastroenterology. 2015 Mar;148(3):590-602.e10
pubmed: 25479137
Liver. 2002;22 Suppl 2:20-5
pubmed: 12220298
Int J Artif Organs. 2021 Aug;44(8):560-564
pubmed: 33302765
Ann Intensive Care. 2021 Jan 18;11(1):10
pubmed: 33462764
Nat Med. 2014 May;20(5):518-23
pubmed: 24728410
Ann Intensive Care. 2018 Nov 15;8(1):109
pubmed: 30443736
Ann Pharmacother. 2018 Dec;52(12):1204-1210
pubmed: 29871503
Artif Organs. 2021 May;45(5):E101-E112
pubmed: 33190288
J Hepatol. 2005 Feb;42(2):195-201
pubmed: 15664244
Diagn Microbiol Infect Dis. 2014 Sep;80(1):72-8
pubmed: 24974271
Liver Int. 2003;23 Suppl 3:16-20
pubmed: 12950956
Gastroenterology. 2015 Mar;148(3):603-615.e14
pubmed: 25479139
Artif Organs. 2014 Feb;38(2):125-34
pubmed: 23834711
Liver Int. 2019 Jul;39(7):1271-1280
pubmed: 30825255
World J Crit Care Med. 2020 Jan 31;9(1):1-12
pubmed: 32104647
Lancet. 2015 Oct 17;386(10003):1576-87
pubmed: 26423181
Liver Transpl. 2008 Oct;14 Suppl 2:S67-79
pubmed: 18825677
Liver Int. 2020 Jun;40(6):1457-1466
pubmed: 32162397
J Hepatol. 2017 May;66(5):1047-1081
pubmed: 28417882
J Immunol. 2016 Nov 15;197(10):3755-3761
pubmed: 27815438
J Hepatol. 2015 Apr;62(1 Suppl):S131-43
pubmed: 25920082
Liver Int. 2003;23 Suppl 3:39-43
pubmed: 12950960
Liver Transpl. 2004 Sep;10(9):1109-19
pubmed: 15350001
J Clin Med. 2022 Feb 16;11(4):
pubmed: 35207301
Sci Rep. 2021 Feb 18;11(1):4189
pubmed: 33602961
J Clin Med. 2020 May 20;9(5):
pubmed: 32443729
World J Gastroenterol. 2016 Jul 14;22(26):5958-70
pubmed: 27468190
Liver Transpl. 2001 Dec;7(12):1034-9
pubmed: 11753905